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Abstract
Genome-wide association studies (GWAS) of colorectal cancer (CRC) have led to the identification of a number of common
variants associated with modest risk. Several risk variants map within the vicinity of TGFb/BMP signaling pathway genes,
including rs4939827 within an intron of SMAD7 at 18q21.1. A previous study implicated a novel SNP (novel 1 or rs58920878)
as a functional variant within an enhancer element in SMAD7 intron 4. In this study, we show that four SNPs including novel
1 (rs6507874, rs6507875, rs8085824, and rs58920878) in linkage disequilibrium (LD) with the index SNP rs4939827
demonstrate allele-specific enhancer effects in a large, multi-component enhancer of SMAD7. All four SNPs demonstrate
allele-specific protein binding to nuclear extracts of CRC cell lines. Furthermore, some of the risk-associated alleles correlate
with increased expression of SMAD7 in normal colon tissues. Finally, we show that the enhancer is responsive to BMP4
stimulation. Taken together, we propose that the associated CRC risk at 18q21.1 is due to four functional variants that
regulate SMAD7 expression and potentially perturb a BMP negative feedback loop in TGFb/BMP signaling pathways.
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116 CRC cell line and human CRC neoplastic explants, and
reduced tumorigenesis in the APCmin/- mouse [7].
CRC GWAS have led to the identification of several genomic
regions associated with risk that include genes in the TGFb
signaling pathway including SMAD7, BMP2, BMP4, and
GREM1 [8–14]. This includes single nucleotide polymorphism
(SNP) rs4939827, located in SMAD7 intron 4, which has been
reported in multiple studies. Pittman et al. reported that a novel
SNP (termed novel 1, later renamed rs58920878) mapped to an
enhancer element that drove GFP expression in Xenopus tadpole
muscles and colorectum in an allele specific manner, implicating
rs58920878 as a functional variant within this region [15].
Prompted by our discovery of multiple functional variants
within the 11q23 CRC GWAS region [16], we comprehensively
examined the genomic region surrounding the CRC tagSNP
rs4939827 at 18q21.1 for other potential functional SNPs. We
identified 4 SNPs, rs6507874, rs6507875, rs8085824 and
rs58920878 (novel 1), in a region of approximately 2 kb, each
demonstrating allele-specific enhancer activity. We further determined that alleles corresponding to the risk haplotype correlated
with increased expression of SMAD7 in normal colon epithelial
tissues. Sequences encompassing all four SNPs also bound to

Introduction
TGFb signaling has long been associated with colorectal cancer
(CRC). In addition to canonical roles in the regulation of
apoptosis, cell differentiation, and cell growth of intestinal
epithelium, TGFb signaling is an important player in the immune
response and inflammatory bowel disease, a risk factor for CRC
(reviews [1–3]). TGFb and BMP signaling define the two major
branches of the TGFb pathway. Activation of either branch leads
to the recruitment of R-SMADs, SMAD2/3 in the case of TGFb
or SMAD1/5/8 in the case of BMPs, which form a complex with
SMAD4. This complex then directs the transcription of many
target genes, including SMAD7. SMAD7, an inhibitory SMAD
like SMAD6, in turn serves as a negative feedback regulator of
TGFb and BMP signaling, in addition to acting as a crosstalk node
with other pathways including TNF [4,5].
SMAD7 also plays other important roles in the etiology of
CRC, such as interacting with b-catenin to regulate MYC
expression and WNT signaling [6]. SMAD7 overexpression has
been seen in some CRC cells, and reduction of SMAD7 expression
using anti-sense RNA leads to decreased proliferation in the HCT-
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was changed from C to G. While the minor alleles for SNPs
rs6507874 (T, minor allele frequency (MAF) = 0.44) and
rs58920878 (G, MAF = 0.34) showed a lower enhancer activity,
the minor alleles for SNP rs8085824 (C, MAF = 0.34) and
rs6507875 (C, MAF = 0.49) showed a higher enhancer activity in
these assays.
Fragment A encompasses several smaller distinct HCT-116
H3K4me1 peaks, with the left-most peak specific to HCT-116
when compared to the layered H3K4me1 super-track of 7
ENCODE Tier 1 cell lines [19] (Figure 1D). To test the relative
contributions of these regions and SNPs individually on overall
enhancer activity, 4 smaller constructs, A1–A4, were designed
(Figure 1D). The A1 fragment includes SNPs rs6507874 and
rs6507875 and encompasses the HCT-116 specific peak. These
two SNPs are only separated by 13 bp, and are in LD with one
another with r2 = 0.794, D9 = 1. As shown in Figure 3A, the A1
fragment demonstrated enhancer activity. The major haplotype of
rs6507874 and rs6507875 alleles in the CEU population, CG,
demonstrated the lowest level of enhancer activity compared to the
other three possible allele combinations (Figure 3B). The TC and
CC minor haplotypes showed approximately 1.3–1.5 fold and 2–
2.5 fold higher activity in both cell lines, HCT-116 and SW480,
respectively (Figure 3B). The TG allele combination, while not a
known CEU haplotype, showed lower activity than the TC
haplotype. Taken together, we conclude that while both SNPs,
rs6507874 and rs6507875, contribute to the overall enhancer
activity level of the A1 fragment, rs6507875 alleles show a larger
allele-specific effect than rs6507874, in the direction consistent
with the 2 kb fragment (Figure 2C). In contrast, the effect of the
rs6507874 allele on enhancer activity was dependent upon which
rs6507875 allele was present, suggesting a contextual effect within
the enhancer components. These data imply a complex functional
relationship exists between adjacent SNPs.
The A2 fragment contains SNP rs8085824 and straddles the
region between the two most prominent HCT-116 H3K4me1
peaks in enhancer A (Figure 1D). While fragment A2 had activity
on its own, it showed the lowest activity of the 4 sub-regions tested
(Figure 3A). When the rs8085824 allele was changed from T
(major allele) to C (minor allele), activity increased two fold
(Figure 3C) consistent with results for the larger fragment
(Figure 2C). The A3 fragment encompasses the A2 region
(including rs8085824) and a further 160 bp to include
rs58920878. This fragment showed 2 fold more activity than the
A2 fragment. The major haplotype of rs8085824 and rs58920878
(r2 = 1, D9 = 1, CEU) is TC. The minor haplotype CG demonstrated 1.3 to 1.6 fold higher activity than the major haplotype in
HTC-116 and SW480 cells, respectively. The artificially constructed CC allele combination had the highest level of activity
tested for the A3 fragment. Comparing the CC fragment to the
TC and CG haplotype fragments, we observed that a larger drop
in activity resulted from changing the rs8085824 allele than
rs58920878. Conversely, changing rs58920878 in the TC haplotype to TG did not result in a significant difference in enhancer
activity. As with the A2 fragment, for SNP rs8085824 these results
were consistent with allele-specific effects seen using the larger
fragment (Figure 2C). However, for SNP rs58920878, the effect
predicted by the 2 kb fragment was dependent upon which
rs8085824 allele was present, again, suggesting that a complex
functional relationship exists between adjacent SNPs.
Finally, fragment A4, encompassing the second smaller HCT116 H3K4me1 peak, contained only SNP rs58920878 and
demonstrated similar activity to fragments A1 and A3 (Figure 3A).
This fragment showed enhancer activity was reduced 3 fold when
the major allele C was changed to the minor allele G (Figure 3E).

nuclear proteins from CRC cell lines in an allele-specific manner
in electrophoretic mobility shift assays (EMSAs). Finally, we
showed that the enhancer was responsive to BMP4-induced
signaling in luciferase assays, while neither haplotype was
responsive to TGFb1. Taken together, we propose that the
CRC risk at chromosome 18q21.1 is due to the contributions of 4
functional variants in an enhancer affecting the expression of
SMAD7, potentially leading to perturbed regulation of the BMP
negative feedback loop in BMP/TGFb signaling pathways.

Results
Region Analysis
The index SNP rs4939827 associated with CRC at chromosome 18q21.1 lies within intron 4 of the SMAD7 gene. There are
20 SNPs in LD with rs4939827 with an r2$0.2 in the CEU
population (1000 Genomes Project, June 2011 release), our
selected LD threshold for potential functional candidates (Figure 1A and 1C). All 21 SNPs lie within a 16 kb region of the
SMAD7 intron 4. In order to identify potential genomic regulatory
sequences from this region, the SNPs in LD with rs4939827 were
aligned with chromatin immunoprecipitation and sequencing
(ChIP-seq) tracks for histone methylation and acetylation marks
associated with enhancers, H3K4me1 and H3K27ac (Figure 1B).
For this study, we referenced Sigmoid Colon H3K27 acetylation
from the Roadmap Epigenomics Consortium [17], and CRC cell
lines SW480 and HCT-116 H3K4 monomethylation generated in
our laboratory and from the ENCODE project, respectively
[16,18,19]. Several potential enhancer peaks containing SNPs in
LD with rs4939827 were identified in sigmoid colon, SW480, or
HCT-116 cells, including a 2kb region containing rs58920878
(green stripe, Figure 1B). In order to characterize the region
comprehensively, smaller peaks below the threshold for peak
calling software were also cloned and tested for activity if they
contained a SNP meeting our LD cut-off. DNase I hypersenstitivity tracks from the ENCODE project were also aligned, but
no peaks overlapped with any of the candidate SNPs in LD with
rs4939827 [20,21].

Enhancer Activity Assays
Seven putative enhancer regions were cloned into a luciferase
assay vector to determine enhancer activity in CRC cell lines
HCT-116 and SW480. Only the 2 kb fragment (green stripe in
Figure 1B) at the 39 end of SMAD7 intron 4 showed activity in our
assays, but only in the reverse orientation (Figure 2A). Regions
tested but lacking activity in this assay are indicated in red stripes
on Figure 1B (Figure 2B). The 2 kb enhancer region, we term
fragment A, contains 4 SNPs in LD with rs4939827: rs6507874,
rs6507875, rs8085824, and rs58920878 (novel 1). An expanded
view of fragment A is shown in Figure 1D. As shown in Figure 1C,
these four SNPs are in LD (r2 = 1 to 0.494) with one another and
define 5 haplotypes in the CEU population. These haplotypes are
shown in relation to the rs4939827 variant (risk allele T) in
Figure 1E [22,23].
We first tested whether there were any allele-specific differences
in enhancer activity for each of the SNPs individually starting with
a 2 kb fragment with all 4 SNPs containing C alleles. While this
haplotype is not seen in the CEU population, this allele
combination showed the highest enhancer activity of all fragments
tested. We observed allele-specific changes in enhancer activity for
each of the four variants when alleles were changed by site
directed mutagenesis (Figure 2C). All 4 SNPs showed a decrease
in enhancer activity when alleles were changed to the alternate
form. The largest decrease in activity was seen when rs58920878
PLOS ONE | www.plosone.org
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Figure 1. Chromatin features and LD structure for the 18q21.1 CRC GWAS locus. (A) The SMAD7 gene depicted with genomic coordinates
(hg19) and the position of SNPs in LD (r2$0.2, CEU population) with tagSNP rs4939827. (B) UCSC Genome Browser view of SMAD7 with SNPs in LD
with rs4939827 indicated. ChIP-seq tracks for enhancer histone marks are Sigmoid Colon (SC) H3K27ac from REMC/UCSD for the Roadmap
Epigenomics Consortium, SW480 (SW) H3K4me1, and HCT-116 (HCT) H3K4me1 from the ENCODE consortium. DNase I hypersensitivity tracks HCT116 (HCT) and CaCo-2 below are from the UW ENCODE dataset. The green stripe represents the enhancer fragment A. Red stripes indicate cloned
fragments B to G (left to right) that were shown to lack enhancer activity. Coordinates for each fragment are provided in File S1. (C) Linkage
disequilibrium plot for rs4939827 including all SNPs in 1KG project with r2$0.2, created with Haploview. r2 = 1- black, 1.r2.0.2 - grey scale. (D)
Zoomed view of fragment A showing sub-fragments A1–A4. The ENCODE Layered H3K4me1 track of 7 cell lines is shown to identify cell-type specific
peaks. (E) Haplotypes and percentages (CEU population) for the 4 SNPs in fragment A and rs4939827. Haplotypes associated with the rs4939827 risk
allele T are in light purple.
doi:10.1371/journal.pone.0111914.g001

prominent of the specific bands are marked in the margins with
arrows.
In the case of rs6507874 and rs58920878 (Figure 4A, 4D), there
were complexes found in HCT-116 and SW480, which were not
seen in RKO. This may explain why haplotype specific activity
was not seen in the RKO luciferase activity experiment. In
Figures 4A and S2, the band marked by the arrow was specific to
the rs6507874 C allele probe. Note that in HCT-116 and RKO
extracts, even 200-fold excess of the unlabeled T allele oligonucleotide could not out-compete the C allele for binding. For the
rs6507875 probes (Figure 4B and S3), while there were specific
bands for both alleles (arrows), the G allele bound with more
affinity than the C allele. Interestingly, rs6507875 probes bound
strongly to components of the RKO extract, even in the presence
of excess unlabeled DNA (Figure 4B).
For the rs8085824 probes, we again found several specific
complexes for each allele. One prominent complex, marked by the
bottom arrow, showed that the C allele probe was not completely
outcompeted with 200-fold excess of the T allele. It appears that
the bound proteins of this complex are found in higher amounts in
SW480 and HCT-116 than RKO nuclear extracts. In the case of
the rs58920878 probes, we found several bands specific for the C
allele, while the G allele was found predominantly in larger
complexes (higher bands) than the C allele.
Determining the identity of these allele-specific binding proteins
will be required to fully understand the action of the SMAD7
enhancer. Protein binding prediction software Biobase Match,
based on the TRANSFAC motif database, was used to identify
candidates for each SNP region [24]. Results of this analysis are
presented as Tables S1, S2 and S3 in File S1. The DNA binding
protein with the top difference in predicted binding scores between
alleles for rs6507874/rs6507875 (analyzed together due to
proximity) was NF-1A, for rs8085824 was Churchill, and for
rs58920878 was ZF5. However, for each locus, none of the
proteins with the greatest predicted allele differences were the
proteins with the highest core or matrix scores for each sequence.

The A4 fragment containing rs58920878 was the only one of the
smaller fragments where the minor allele or haplotype demonstrated lower activity than the major allele/haplotype.
The two most common haplotypes in CEU for this group of
4 SNPs are CGTC (49.9%) and TCCG (33.4%) (Figure 1E).
These combinations were tested in the context of the 2 kb
enhancer A construct. As shown in Figure 3F, overall the major
CGTC haplotype demonstrated higher enhancer activity than the
minor TCCG haplotype in HCT-116 and SW480. Interestingly,
when we tested the two haplotypes in the CRC cell line RKO,
CGTC was not significantly more active than the TCCG
haplotype, indicating there was some specificity to fragment A
activity even amongst CRC cell lines. Neither haplotype of
fragment A was active in non-CRC cell line HEK293 that served
as a negative control (Figure S1A). Fragments containing
haplotypes TCTC (9.5% of CEU population) and CCTC (5.9%
of CEU population) demonstrated activity levels between that of
haplotypes CGTC and TCCG (Figure S1B).

Electrophoretic Mobility Shift Assays
To better understand these allele-specific enhancer effects, we
next investigated the nuclear protein binding to the sequences
containing each of the 4 SNPs, rs6507874, rs6507875, rs8085824,
and rs58920878. We hypothesized that transcription factors would
selectively bind to the C alleles with higher affinity, as the 2 kb
fragment and fragments A1–A4 with C alleles showed the highest
level of enhancer activity. Conversely, inhibitory proteins may
bind to the T or G alleles preferentially to negatively regulate
enhancer activity. To this end, 33 bp double stranded oligonucleotides centered on each SNP, were synthesized. In each case, the
C allele was labeled with the red (700) IR dye. The alternate
alleles, either T or G were labeled with green (800) IR dye
(individual channels are presented as black and white images in
Figures S2–S5 for ease of reproduction and analysis). Nuclear
extracts were prepared from SW480, HCT-116 and RKO CRC
cell lines and incubated with non-specific and specific unlabeled
competitor DNA as indicated in Figure 4. The two alleles of each
SNP are labeled with different colors, allowing a direct comparison
of the binding of each allele to nuclear proteins in the same
reaction. As shown in Figure 4, for each probe set tested, there are
bands specific to one allele versus the other allele.
For each allele set, lanes 3, 4, 9, 10, 15 and 16 show a single
allele probe incubated with the nuclear extract. Lanes 5–8, 11–14,
and 17–20 contain reactions with 1:1 amounts of each labeled
allele. To determine specificity of the shifted complexes, unlabeled
competitive oligonucleotides for each allele were added in 200-fold
excess. Lanes 6, 12, and 18 contain the unlabeled C alleles and
lanes 7, 13 and 19 contain the unlabeled T or G alleles. In lanes 8,
14, and 20, an unlabeled competitor of similar base composition
but not matching any of the sequences was added in an equal
amount. Bands that disappeared when competed with either SNP
allele, but present with the unrelated (non-specific) competitor
were considered specific for the SNP sequence. The most
PLOS ONE | www.plosone.org

eQTL Analysis in Normal Colon Tissue
We next asked if the genotype at these SNPs correlated with
gene expression levels in normal colon tissues. As the enhancer is
located in intron 4 of the SMAD7 gene, SMAD7 was an obvious
candidate target gene. In addition to rs6507874, rs6507875 and
rs8085824, we also genotyped the tagSNP rs4939827 in pathologically normal human tissue samples obtained from surveillance
colonoscopy through the Aspirin/Folate Polyp Prevention Study
[25–27]. We were unable to design a TaqMan assay for
rs58920878, however SNPs rs8085824 and rs58920878 are in
perfect LD (r2 = 1, D9 = 1); therefore rs8085824 also represents a
proxy for rs58920878. No statistically significant correlation
between expression of the two other genes within 0.5 Mb of
rs4939827, CTIF or DYM, and any of the genotyped SNPs was
seen (data not shown).
4
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Positive controls are shown for each group of constructs analyzed on
the same plate. Fragment E contains the tagSNP rs4939827. (C) Activity
of fragment A in the reverse orientation with all SNPs in the fragment
with their C allele, with each allele changed independently to the
alternate allele, shown as fold change relative to the construct
containing the four C alleles. All four alleles result in a statistically
significant reduction in activity: rs6507874 T p = 8.2561023 (HTC-116),
p = 3.30610 22 (SW480); rs6507875 G p = 3.40610 22 (HCT-116),
p = 6.79610 23 (SW480); rs8085824 T p = 1.20610 22 (HCT-116),
p = 3.1261023 (SW480); rs58920878 G p = 2.0961023 (HCT-116),
p = 3.0561023 (SW480).
doi:10.1371/journal.pone.0111914.g002

We found that the tagSNP rs4939827 did not show a statistically
significant association with SMAD7 expression levels, although
higher expression trended with the T GWAS risk allele
(p = 0.1130) (Figure 5). However, SNP rs8085824 C (minor) allele
demonstrated a statistically significant correlation (p = 0.01197)
with increased SMAD7 expression. Given that SNPs rs8085824
and rs58920878 are in perfect LD, this result can be extrapolated
to imply a correlation between rs58920878 G (minor) allele and
higher levels of SMAD7 expression. The rs6507874 T (minor)
allele (p = 0.07531) and the rs6507875 C (minor) allele (p = 0.1337)
did not show a statistically significant correlation with increased
SMAD7 expression. Note that overall the TCCG haplotype
(minor haplotype) correlated with higher SMAD7 expression in
tissues and in luciferase assays in the context of fragments A1, A2,
and A3, but was opposite to the effect seen for enhancer activity of
the 2 kb fragment in luciferase experiments where the fragment
containing the TCCG haplotype (minor haplotype) correlated
with reduced enhancer activity compared to the fragment
containing the CGTC haplotype.
Further studies will be needed to determine how this multicomponent enhancer controls SMAD7 gene expression during
colon development and cell growth, and to determine whether or
not the individual components of the enhancer act independently
of one another.

Regulation of the SMAD7 Enhancer
We next wanted to determine the relationship between
enhancer activity and BMP/TGFb signaling. As mentioned in
the introduction, SMAD7 acts as a key mediator of the negative
feedback loop for both the TGFb and BMP signaling pathways.
We were interested therefore to determine if enhancer A was a
part of a feedback loop, becoming more active in response to
either TGFb1 or BMP4 signaling. HCT-116 and SW480 cells
were serum starved overnight prior to 6 hours of treatment with
100 pmol TGFb1 or BMP4, and the 2 kb fragment A was used to
test for luciferase activity. Following treatment with TGFb1,
fragments containing either the CGTC (major) haplotype or the
TCCG (minor) haplotype demonstrated no statistically significant
change in activity in either cell line (Figure 6A). In contrast,
following treatment with BMP4, enhancer activity of the fragment
containing the CGTC major haplotype was increased 1.2 fold in
HCT-116 cells and 1.5 fold in SW480 cells (Figure 6B). An
increase in enhancer activity was also seen with the fragment
containing the TCCG minor haplotype in SW480 cells where
BMP treatment led to a 1.4 fold increase in enhancer activity, but
not in HCT-116 cells where no significant increase was observed
(p = 0.38) (Figure 6B). Because DNA fragments containing both
haplotypes were stimulated by BMP4 in SW480 to a similar extent
(fold change), we postulate that the 4 SNPs in the risk haplotype
do not disrupt the actual BMP responsive components of the
enhancer. However, due to the deficit in activity with the minor
haplotype, following BMP4 stimulation, the TCCG haplotype
construct still demonstrates lower enhancer activity than the

Figure 2. Fragment A exhibits enhancer activity in the reverse
orientation only. (A) Relative luciferase activity for positive control,
fragment A in the forward, and fragment A in the reverse orientation.
Light columns indicate activity in HCT-116, dark columns indicate
activity in SW480. (B) Fragments B through G, shown in figure 1B as red
stripes do not show enhancer activity in either orientation in HCT-116.
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Figure 3. Fragment A is composed of smaller domains with independent enhancer activity. (A) Fragment A was divided into 4 smaller
DNA fragments, A1–A4, depicted in Figure 1D. Each smaller fragment demonstrated enhancer activity in both HCT-116 (light bars) and SW480 (dark
bars). For the experiment shown, all SNPs contained their C alleles. (B) Activity of Fragment A1 containing rs6507874 and rs6507875, shown as fold
change relative to the major haplotype CG for HCT-116 (light bars) and SW480 (dark bars). The minor haplotype TC (p = 2.2561022 (HCT-116),
p = 8.5961022 (SW480)), and combination CC (p = 5.0661025 (HCT-116), p = 1.7561025 (SW480)) not seen in the CEU population show higher activity
than the major haplotype. Combination TG (p = 0.450 (HCT-116), p = 0.287 (SW480)) demonstrates activity similar to CG. (C) Fragment A2 containing
rs8085824 shows 2-fold higher enhancer activity with the minor C allele of than the major allele T (p = 4.7561023 (HCT-116), p = 3.6161024 (SW480)).
(D) Activity of fragment A3 containing rs8085824 and rs58920878 relative to major haplotype TC. The minor haplotype CG demonstrates higher
activity than TC (p = 2.4961022 (HCT-116), p = 6.3261023 (SW480)). The T (major) allele of rs8085824 shows lower activity than C (minor) allele
regardless of rs58920878 allele. The highest activity is seen in haplotype CC that is not reported in the CEU population (p = 6.3561027 (HCT-116),
p = 1.4761026 (SW480)). (E) Activity of fragment A4 encompasses the peak containing rs58920878. The minor allele G of rs58920878 shows
dramatically less activity than the major C allele (p = 1.9261024 (HCT-116), p = 1.5261025 (SW480)). (F) Fragment A was tested for activity with the
two most common haplotypes (Figure 1E) in the CEU population. The CGTC haplotype shows higher activity in HCT-116 (light bars, p = 1.04610211)
and SW480 (medium bars, p = 8.60610211), but no significant difference in activity in RKO (dark bars).
doi:10.1371/journal.pone.0111914.g003

CGTC haplotype without BMP4 stimulation (Figure 6C). In total,
these data implicate the enhancer in a negative feedback loop in
response to BMP signaling but not in the TGFb arm of the
signaling cascade.

single functional variant [28]. For example, at chromosome
11q23.1, our lab identified two SNPs in LD (r2 = 1) associated with
CRC risk, one in an enhancer and one in a bi-directional
promoter, that demonstrated allele-specific activity and correlated
with expression levels of three previously uncharacterized gene
targets [16]. Furthermore, recent advances in understanding the
biology of enhancers, specifically multi-component, super or
stretch enhancers prompted us to take a deeper look at 18q21.1

Discussion
Recently, our lab and others have begun to consider the effects
of multiple functional variants in linkage disequilibrium (LD)
contributing to disease risk identified through GWAS instead of a
PLOS ONE | www.plosone.org
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Figure 4. Differential protein binding by SNP alleles using EMSA. (A) Nuclear extracts from SW480, HCT-116, and RKO cell lines were
incubated with IR-dye labeled 33mers centered on rs6507874 C (red label) and T (green labels) prior to native EMSA. Lanes 1 and 2 show probe
without nuclear extract. Lanes 3, 4, 9, 10, 15, and 16 show each labeled probe binding to nuclear proteins individually with cell line as noted above.
Lanes 5–8, 11–14, and 17–20 are a 1:1 competition with labeled C and T allele probes. Lanes 6, 12 and 18 contain 200-fold excess unlabeled C allele
competitor. Lanes 7, 13, and 19 contain 200-fold excess unlabeled T allele competitor. Lanes 8, 14, and 20 contain 200-fold excess competitor of an
unmatching sequence with similar nucleotide content. Bands specific for one allele and lost upon competition are marked with arrows. See Figure S2
for red (700) channel image of the C probe and the green (800) channel of the T probe in black and white. (B) As in panel A, with rs6507875 C allele
(red probe) and G allele (green). See Figure S3 for red (700) channel image of the C probe and the green (800) channel of the G probe in black and
white. (C) As in panel A, with rs8085824 C allele (red) and T allele (green). See Figure S4 for red (700) channel image of the C probe and the green
(800) channel of the T probe in black and white. (D) As in panel A, with rs58920878 C allele (red) and G allele (green). See Figure S5 for red (700)
channel image of the C probe and the green (800) channel of the G probe in black and white.
doi:10.1371/journal.pone.0111914.g004

have been identified in the promoter region, and an enhancer in
intron 1 was discovered to have BMP responsiveness dependent on
GATA-family transcription factors [33].
Hnisz et al. recently classified nearly the entire length of the
human SMAD7 gene as a super-enhancer in colon crypts, sigmoid
colon and fetal intestine [29]. Super-enhancers are defined as large
enhancer clusters that define a cell’s identity [29,31]. The 2 kb
enhancer element described in this work is only one segment of
this super-enhancer. Within the 2 kb region, we found smaller
components, each with enhancer activity. We showed that the
activity of these four smaller enhancer elements was modulated by
common SNPs in LD with the CRC risk tagSNP rs4939827. Each
SNP contributed to the overall level of activity of the enhancer by

that contains several histone-modification ChIP-seq peaks associated with active enhancers mapping to SMAD7 intron 4 [29–31].
SMAD7 functions as an important pathway regulation step in
the signaling of the TGFb superfamily. SMAD7 is also a nexus of
crosstalk for other key signaling networks, including WNT and
TNF. Thus, it is not surprising that SMAD7 levels are exquisitely
controlled in tissues given the importance of TGFb/BMP
signaling particularly in colon cells. This control is mediated, in
part, at the gene expression level by multiple enhancer elements
that bind transcription factors and co-activators to respond to
specific cellular conditions and signaling programs. Most studies
characterizing the enhancers that control SMAD7 have been
performed in mouse [32]. BMP and TGFb response elements
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Figure 5. Candidate functional SNPs are association with SMAD7 gene expression levels. Fold change (FC) of SMAD7 expression was
measured in normal colon tissue samples from surveillance colonoscopies. Rank-based non-parametric analysis was used to estimate the effect of
each extra minor allele for rs6507874, rs6507875, rs8085824, and rs4939827 (additive model) on gene expression adjusting for gender, age and race.
Two-sided p-values were obtained from a likelihood ratio test. Log2(DDCt) were plotted as a function of genotypes using a box plot – dot plot
overlay. Number of samples is noted under each genotype. A statistically significant association was found for rs8085824.
doi:10.1371/journal.pone.0111914.g005

binding nuclear proteins, presumably transcription factors, in an
allele-specific manner. How these individual SNP’s effects are
manifest in the colon tissue of an individual is unclear. EMSA
analysis showed unique binding patterns for each sequence
surrounding the SNPs, meaning that each enhancer segment
could be responsive to different cell stimuli. That we did not
always observe a consistent relationship between the alleles of the
4 SNPs under study in both their effect on enhancer activity as
well as their correlation with SMAD7 gene expression implies a
highly complex relationship between these variants, transcription
factor binding and regulation of SMAD7.
The effects of this risk haplotype on CRC development may be
related to a transient cellular condition. We found that fragment A
was responsive to BMP4 stimulation in a manner that exaggerated
the differences between the CGTC and TCCG haplotypes. As
none of the 4 SNPs disrupt a canonical BMP-response element
motif, it remains an open question how this signal is transmitted.
We also do not know how responsiveness in this one enhancer
element interacts with other enhancer, repressor or promoter
elements regulating SMAD7. However, the lack of responsiveness
to TGFb1, and the similar levels of activity for the two haplotypes
in cell line RKO imply that the allele specific enhancer effects are
in response to a specific set of cell conditions. Thus, haplotype
differences could modulate SMAD7 as a negative regulator of
TGFb superfamily signaling. Further studies will be required to
determine if other signaling pathways use this enhancer, and if
they do so, whether those effects are in an allele-specific manner.
It is also important to note that SMAD7 is also a regulator of
TGFb signaling in immune cells that are linked to ulcerative colitis
and inflammatory bowel syndrome, both risk factors for CRC
[34–36]. The role of the enhancer in immune cells in the
subsequent relationship to CRC development is not known.
PLOS ONE | www.plosone.org

We cannot exclude the possibility that there may be additional
functional SNPs within this region that we have not identified.
However, fine mapping studies also identified the region
containing the 4 functional SNPs as being associated with CRC
risk, and rs6507874, rs8085824 and rs58920878 were ranked in
the top ten SNP associations in the region [37]. We did not
account for multiple testing in our eQTL analysis. However, we
argue that Bonferroni testing is unduly conservative due to the fact
that the SNPs in the putative risk haplotype are in very strong LD
(D9 of 0.94–1, 1000 Genomes Project data). We also cannot
conclude that SMAD7 is the only target of the enhancer we
describe in this study as no genome wide analyses of long-range
chromatin interactions to date have been performed. This
emphasizes the need for future studies such as CRISPR/Cas9
knock out of the putative enhancer region to support our
hypothesis that this regulatory element modulates SMAD7
expression.
Several studies have noted that GWAS associated risk SNPs
map to enhancers, particularly super-enhancers, at higher than
random rates. In this study we provide another example of
multiple functional variants mapping to regulatory regions. Also,
when considering colon cancer associated SNPs from GWAS
studies, several are found in the vicinity of other TGFb
superfamily members. If modulation of SMAD7 expression leads
to CRC, as we propose here, it seems natural that signaling targets
of SMAD7 would also be implicated in CRC risk. Identification of
the functional variants tied to the regulation of those genes,
including BMP2 and BMP4, will clarify the role of TGFb
signaling in the etiology of CRC.
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Vermont IRB, University of Southern California IRB, Kaiser
Permanente, Los Angeles IRB, Colorado Multiple IRB, University
of Iowa IRB, University of Minnesota IRB, Minneapolis VAMC
IRB, Allina Health IRB, University of Toronto IRB, Sunnybrook
Hospital IRB, St. Michaels Hospital IRB, Henry Ford Hospital
IRB, University of North Carolina IRB, Cleveland Clinic IRB,
and Kaiser Permanente, Cleveland IRB.

Cell Culture
HCT-116, SW480, and RKO CRC cell lines and the HEK293
cell line were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). HCT-116 and SW480 cells
were grown in McCoy’s 5A (Mediatech) supplemented with 10%
Fetal Bovine Serum (Omega Scientific, Inc.), and 1% Penicillin/
Streptomycin, and incubated at 37uC and 5% CO2. RKO and
HEK293 cells were grown in DMEM (Mediatech) supplemented
with 10% Fetal Bovine Serum (Omega Scientific, Inc.), and 1%
Penicillin/Streptomycin, and incubated at 37uC and 5% CO2.
Cells treated with 100 pM BMP4 (Sigma-Aldrich) or 100 pM
TGFb1 (Sigma-Aldrich) were serum starved overnight prior to
performing luciferase assays or harvesting of nuclear extracts for
EMSA.

Plasmids and Luciferase Assays
DNA fragments corresponding to candidate enhancer regions
were PCR amplified using genomic DNA from a normal
lymphoblastoid cell line (See Supplemental Methods in File S1
for primer sequences). Fragments were amplified and cloned using
CloneAmp HiFi PCR Premix and the In-Fusion HD cloning kit
(Clontech). PCR fragments were subcloned into the Sac II
restriction enzyme site in both directions, upstream of a thymidine
kinase (TK) minimal promoter-firefly-luciferase vector obtained
courtesy of Dr. G. A. Coetzee (USC). PCR fragments were
sequenced in both directions followed by Sanger sequencing to
confirm the presence of the candidate variants and the absence of
any PCR amplification-induced mutations (Genewiz). A region of
Chr 8 served as the negative control [38], and a region of 8q24
which was previously shown to have enhancer activity in HCT116 (AcP 6) served as the positive control [38]. For enhancer
assays SW480 (106104 cells/well), HCT-116, RKO, or HEK293
cells (66104 cells/well) were seeded into 96-well plates. Cells were
co-transfected with reporter plasmids and constitutively active
pRL-TK Renilla luciferase plasmid (Promega) using Lipofectamine 2000 Reagent (Life Technologies) according to the
manufacturer’s instructions. After 24 hrs cells were harvested
and extracts were assayed for luciferase activity using the DualLuciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions, and measured using a Tecan Infinite
F200Pro Microplate Reader. The ratio of luminescence from the
experimental sample to the negative control reporter was
calculated for each sample, and defined as the relative luciferase
activity. Luciferase activity was tested in a minimum of three
independent clones for each construct. The data are presented as
mean 6 SD of at least three independent transfection experiments
each conducted in triplicate. Relative luciferase activity greater
than 2 was considered positive for activity. To assess allele-specific
effects, specific SNP alleles were generated by mutagenesis using
the QuikChange site-directed mutagenesis kit (Agilent Technologies). Plasmids were sequenced and transfected into the cells as
above. The mutagenesis data are presented as mean fold change
6 SD of at least three independent transfection experiments each
conducted in triplicate. Two-side p-values between alleles were
calculated using the student t-test.

Figure 6. Fragment A Enhancer is responsive to BMP4
stimulation but not TGFb1. (A) Enhancer activity was measured by
luciferase assay for the fragment A containing the major (CGTC) and
minor (TCCG) haplotypes in serum starved HCT-116 and SW480 cells
incubated with TGFb1 for 6 hours. Samples are plotted as a fold change
in activity relative to non-treated cells on the same plate. (B) Enhancer
activity was stimulated by 6 hours of BMP4 treatment for the CGTC
haplotype in HCT-116 (p = 4.14610 2 3 ) and SW480 cells
(p = 1.22610210). The TCCG haplotype in fragment A shows lower
levels of stimulation, and only in SW480 (p = 1.6161026). (HCT-116
p = 0.38). Effect of BMP is plotted as fold change over untreated samples
for each haplotype on the same plate. (C) Enhancer activity comparison
between the CGTC and TCCG haplotypes following BMP4 treatment.
Relative luciferase activity was plotted for each haplotype in HCT-116
and SW480 using the same experimental dataset as (B).
doi:10.1371/journal.pone.0111914.g006

Materials and Methods
Tissue collection was approved by the following Institutional
Review Boards of the participating centers and all subjects
provided written informed consent: Dartmouth College Committee for the Protection of Human Subjects, Maine Medical Center
IRB, Beth Israel Deaconess Medical Center Committee on
Clinical Investigations, Lahey Hospital IRB, University of
PLOS ONE | www.plosone.org
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Supporting Information

Electrophoretic Mobility Shift Assay (EMSA)
Near-infrared dye (Li-Cor Bioscience) labeled EMSA oligonucleotide probes spanning the SNPs rs6507874, rs6507875,
rs8085824, and rs58920878 were synthesized by Integrated
DNA Technologies and annealed in 1X TE (see Supplemental
Methods in File S1 for sequences). Nuclear extracts from
HCT116, SW480, and RKO CRC cell lines were prepared using
the NE-PER nuclear and cytoplasmic extraction kit (Pierce,
Thermo Scientific). Binding reactions containing 10X binding
buffer (100 mM Tris, 500 mM KCL, 10 mM DTT, pH 7.5), 1mg
poly(dINdC), 2.5 mM DTT/0.25% Tween 20, and 5 mg nuclear
extract were preincubated with 20 pmol unlabeled competitor
DNA at room temperature for 10 minutes. IRDye labeled oligos
were added (50 fmol per oligo) and reactions were incubated in
darkness for 20 min at room temperature prior to addition of 10X
Orange loading dye (Li-Cor Biosciences). Complexes were
resolved on a 6% native polyacrylamide gel run at 200 V for
90 min at 4u in 0.5X TBE and imaged in the glass plates using a
Li-Cor Odyssey Imager.

Figure S1 (A) Fragment A does not exhibit enhancer activity in
HEK293 cells. The 2 kb fragment containing either the CGTC
(major) or TCCG (minor) haplotype does not demonstrate
enhancer activity in the non-colon derived cell line HEK293.
(B) Fragment A haplotypes TCTC (9.5% in CEU population) and
CCTC (5.9% in CEU population) demonstrate activity levels
between that of the major CGTC and TCCG haplotypes. Light
bars represent cell line HCT-116 and dark bars represent SW480.
(TIF)
Figure S2 Differential protein binding by rs6507874
alleles using EMSA. (A) Nuclear extracts from SW480, HCT116, and RKO cell lines were incubated with IR-dye labeled
33mers centered on rs6507874 C (red label) and T (green labels)
prior to native EMSA as labeled. Unlabeled competitors are in
200-fold excess to labeled probes. Competitor X is an unmatching
sequence with similar nucleotide content. Top panel shows the gels
as a merged color image. Middle panel shows the red (700)
channel image of the C probe in black and white, and bottom
panel shows the green (800) channel of the T probe in black and
white, for reproduction clarity. Bands specific for one allele and
lost upon competition are marked with arrows.
(TIF)

DNA and RNA Isolation
RNA and DNA were extracted from 320 fresh frozen tissue
biopsies of normal colorectal mucosa that were obtained from
surveillance colonoscopy as part of the Aspirin/Folate Polyp
Prevention Study [26,27]. The tissue was homogenized using the
Precellys Minilys bead mill (Bertin Technologies) and total RNA
was extracted using the mirVana kit (Life Technologies). Genomic
DNA was extracted using the MELT kit (Life Technologies). The
Aspirin/Folate Polyp Prevention Study was approved by the
Institutional Review Boards of the participating centers and all
subjects provided written informed consent.

Figure S3 Differential protein binding by rs6507875
alleles using EMSA. (A) Nuclear extracts from SW480, HCT116, and RKO cell lines were incubated with IR-dye labeled
33mers centered on rs6507875 C (red label) and G (green labels)
prior to native EMSA as labeled. Unlabeled competitors are in
200-fold excess to labeled probes. Competitor X is an unmatching
sequence with similar nucleotide content. Top panel shows the gels
as a merged color image. Middle panel shows the red (700)
channel image of the C probe in black and white, and bottom
panel shows the green (800) channel of the G probe in black and
white, for reproduction clarity. Bands specific for one allele and
lost upon competition are marked with arrows.
(TIF)

Genotyping
The genotypes of rs6507874, rs6507875, rs8085824, and
rs4939827 were determined using TaqMan SNP genotyping
assays (Life Technologies) and the Type-it Fast SNP Probe PCR
Kit (Qiagen). Assays were read using an Applied Biosystems
7900HT Real Time Instrument and analyzed with the manufacturer’s software, SDS2.3 (Life Technologies).

Figure S4 Differential protein binding by rs8085824
alleles using EMSA. (A) Nuclear extracts from SW480, HCT116, and RKO cell lines were incubated with IR-dye labeled
33mers centered on rs8085824 C (red label) and T (green labels)
prior to native EMSA as labeled. Unlabeled competitors are in
200-fold excess to labeled probes. Competitor X is an unmatching
sequence with similar nucleotide content. Top panel shows the gels
as a merged color image. Middle panel shows the red (700)
channel image of the C probe in black and white, and bottom
panel shows the green (800) channel of the T probe in black and
white, for reproduction clarity. Bands specific for one allele and
lost upon competition are marked with arrows.
(TIF)

Expression Quantitative Trait Loci (eQTL) Analysis
Following quantitation, 308 samples had sufficient RNA to
proceed to cDNA synthesis using 250 ng of total RNA with the
High Capacity RNA-to-cDNA kit (Life Technologies). cDNA
samples were then preamplified with TaqMan Preamp Master
Mix and 96 TaqMan Gene Expression Assays (Life Technologies),
and loaded on a microfluidics chamber for real time PCR analysis
(96.96 Dynamic Array and BioMark HD system, Fluidigm).
Relative quantity of expression of SMAD7 (Hs00998193_m1),
CTIF (Hs00969548_m1), and DYM (Hs00214264_m1) was
measured using the comparative CT Method (DDCT). Expression
was normalized using beta-Glucuronidase (Hs00939627_m1),
determined to show stable gene expression (0.221) in normal
colon tissues using NormFinder [39]. The effect of each minor
allele (0, 1 or 2) on fold change (FC) was evaluated using a rankbased non-parametric analysis and assuming an additive genetic
model [40]. Linear regression modeling of the SNP genotype by
the rank-transformed log2(DDCt) was adjusted for age, gender and
race. Test for significance was obtained from a likelihood ratio test
and a 2-sided p-value ,0.05 was considered statistically significant. Log2(DDCt) was plotted as a function of genotypes using a
box plot – dot plot overlay. All data were analyzed with R 12.13.1
using the SNPassoc package.
PLOS ONE | www.plosone.org

Figure S5 Differential protein binding by rs58920878
alleles using EMSA. (A) Nuclear extracts from SW480, HCT116, and RKO cell lines were incubated with IR-dye labeled
33mers centered on rs58920878 C (red label) and G (green labels)
prior to native EMSA as labeled. Unlabeled competitors are in
200-fold excess to labeled probes. Competitor X is an unmatching
sequence with similar nucleotide content. Top panel shows the gels
as a merged color image. Middle panel shows the red (700)
channel image of the C probe in black and white, and bottom
panel shows the green (800) channel of the G probe in black and
white, for reproduction clarity. Bands specific for one allele and
lost upon competition are marked with arrows.
(TIF)
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Supporting Tables. Constructs and oligonucleotides
used in this study. Tables S1, S2, and S3 showing differential
transcription factor binding candidates.
(PDF)
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